# INTERSTITIAL LUNG DISEASE

## WORKUP OF ILD (_Thorax_ 2008;63:v1)

>_May present as incidental finding, subacute dyspnea, or rapidly progressive hypox. resp fail._

## Broad categories

• (1) **Sarcoid;** (2) **Exposure-related** (eg, drugs, XRT, organic & inorganic dusts);

(3) **Collagen vascular dis.** (eg, scleroderma, GPA, RA); (4) **Idiopathic PNAs** (eg, IPF)

## Rule out mimickers of ILD

• **Congestive heart failure** (✔ BNP, trial of diuresis); **infection:** viral, atypical bacterial; **malignancy:** lymphangitic carcinomatosis, bronchoalveolar, leukemia, lymphoma

## History and physical exam

• Occupational, exposures (eg, birds), tobacco, meds, XRT, FHx, precipitating event

• Tempo (acute → infxn, CHF, hypersens pneumonitis, eos PNA, AIP, COP, drug-induced)

• Extrapulm signs/sx (skin Δs, arthralgias, arthritis, myalgias, muscle weakness, clubbing)

## Diagnostic studies (see Appendix & Radiology inserts)

• CXR and **high-resolution chest CT**

> Upper lobe predom: hypersensitivty pneumonitis, coal, silica, smoking-related ILD

> Lower lobe predom: IPF, NSIP, asbestosis

> Adenopathy: malignancy, sarcoidosis, berylliosis, silicosis

> Pleural disease: collagen-vascular diseases, asbestosis, infections, XRT

• 肺功能: ↓ DLCO (_early sign_), restrictive pattern (↓ volumes), ↓ PaO2 (esp. with exercise); If restrictive + obstructive, consider sarcoid If combined pulmonary fibrosis and emphysema (CFPE) → near-nl lung vol on 肺功能

• Serologies: ✔ ACE, ANA, RF, ANCA, CCP, SSA/SSB, Scl 70, CK, aldolase, myositis panel

• If diffuse alveolar hemorrhage (DAH), Hb typically ↓ 1-2 g/dL

• Bronchoalveolar lavage: dx infxn, hemorrhage, eosinophilic syndromes

• Bx (transbronch, CT-guided, VATS depending on location of findings) if unclear etiology

# SPECIFIC 原因 OF ILD

## Sarcoidosis (_Lancet_ 2014;383:1155)

• Prevalence: African Americans, northern Europeans, and females; onset in 3rd\-5th decade

• 病生理: depression of cellular immune system peripherally, activation centrally

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>臨床表現 of Sarcoidosis</b></p></td></tr><tr><td><p><b>Organ System</b></p></td><td><p><b>表現</b></p></td></tr><tr><td><p><b>Pulmonary</b></p></td><td><p>Hilar LAN; fibrosis; pulm hypertension. Stages: I = bilat hilar</p><p>LAN; II = LAN + ILD; III = ILD only; IV = diffuse fibrosis.</p></td></tr><tr><td><p><b>Cutaneous</b> (~15%)</p></td><td><p>Waxy skin plaques; lupus pernio (violaceous facial lesions)</p><p>Erythema nodosum (red tender nodules due to panniculitis, typically on shins). Ddx: idiopathic (34%), infxn (33%, strep, TB), sarcoid (22%), drugs (OCP, PCNs), vasculitis (Behçet’s), IBD, lymphoma.</p></td></tr><tr><td><p><b>Ocular</b> (10–30%)</p></td><td><p>Anterior &gt; posterior uveitis; ↑ lacrimal gland</p></td></tr><tr><td><p>Endo &amp; renal (10%)</p></td><td><p>Nephrolithiasis, hypercalcemia (10%), hypercalciuria (40%) Due to vitamin D hydroxylation by macrophages</p></td></tr><tr><td><p>Neuro (10% clin, 25% path)</p></td><td><p>CN VII palsy, periph neuropathies, CNS lesions, seizures</p></td></tr><tr><td><p>Cardiac (5% clin, 25% path)</p></td><td><p>Conduction block, VT, CMP</p></td></tr><tr><td><p>Liver, spleen, BM</p></td><td><p>Granulomatous hepatitis (25%), splenic &amp; BM gran. (50%)</p></td></tr><tr><td><p>Constitutional</p></td><td><p>Fever, night sweats, anorexia &amp; wt loss (a/w hepatic path)</p></td></tr><tr><td><p>Musculoskeletal</p></td><td><p>Arthralgias, periarticular swelling, bone cysts</p></td></tr></tbody></table>

• _Löfgren’s syndrome:_ erythema nodosum + hilar adenopathy + arthritis (good prognosis)

• Diagnostic studies: **LN bx** → **noncaseating granulomas** + multinucleated giant cells Endobronchial ultrasonography superior to conventional bronch (_JAMA_ 2013;309:2457)

18FDG PET can be used to identify extent and potentially targets for dx bx

↑ **ACE** (Se 60%, 90% with active dis., Sp 80%, false ⊕ in granulomatous diseases)

• To assess extent: CXR, 肺功能, full ophtho exam, ECG, CBC (lymphopenia, ↑ eos), Ca, 24-h urine for Ca, LFTs; ± Holter, echo, cardiac MRI, brain MRI, etc., based on signs and symptoms

• Rx: **steroids** if sx or extrathoracic organ dysfxn (eg, prednisone 20–40 mg/d), improves sx, but doesn’t Δ long-term course; hydroxychloroquine for extensive skin disease; MTX, AZA, mycophenolate, or anti-TNF for chronic/refractory disease

• Prognosis: ~2/3 spontaneously remit within 10 y (60–80% of stage I, 50–60% stage II, 30% stage III), with relapses uncommon; ~1/3 have progressive disease

## Exposure

• **Drugs/Iatrogenic**

**Amiodarone:** interstitial pneumonitis ↔ org. PNA ↔ ARDS; Rx: d/c amio; steroids

Other drugs: nitrofurantoin, sulfonamides, INH, hydralazine

Chemo: bleomycin, busulfan, cyclophosphamide, MTX, immunotherapy, XRT

• **Pneumoconioses** (inorganic dusts) (_NEJM_ 2000;342:406; _Clin Chest Med_ 2004;25:467)

Coal worker’s: upper lobe coal macules; may progress to massive fibrosis

Silicosis: upper lobe opacities ± eggshell calcification of lymph nodes; ↑ risk of TB

Asbestosis: lower lobe fibrosis, calcified pleural plaques, DOE, dry cough, rales on exam. Asbestos exposure → pleural plaques, benign pleural effusion, diffuse pleural thickening, rounded atelectasis, mesothelioma, lung Ca (esp. in smokers).

Berylliosis: multisystemic granulomatous disease that mimics sarcoidosis

• **Hypersensitivity pneumonitides** (organic dusts): loose, noncaseating _granulomas_

Antigens: farmer’s lung (spores of thermophilic actinomyces); pigeon fancier’s lung (proteins from feathers and excreta of birds); humidifier lung (thermophilic bacteria)

## Collagen vascular diseases (_Chest_ 2013;143:814)

• **Rheumatologic disease**

Scleroderma: fibrosis in ~50%; PHT seen in ~10% of CREST 病人

PM-DM: ILD & skin/muscle findings; MCTD: PHT & fibrosis

SLE & RA: pleuritis and pleural effusions more often than ILD; SLE can cause DAH

• **Vasculitis** (can 表現為 _DAH_)

Granulomatosis with polyangiitis (GPA): ⊕ c-ANCA with necrotizing granulomas

Eosinophilic GPA (EGPA): ⊕ c- or p-ANCA with eosinophilia & necrotizing granulomas

Microscopic polyangiitis: ⊕ p-ANCA without granulomas

• **Goodpasture’s syndrome** = DAH + RPGN; typically in smokers; ⊕ anti-GBM in 90%

• **Lymphangioleiomyomatosis** (LAM): cystic, ↑ in ♀, Rx with sirolimus (_NEJM_ 2011;364:1595)

## Idiopathic interstitial pneumonias (IIPs) (_AJRCCM_ 2013;188:733)

• 定義: **ILD of unknown cause;** dx by radiographic, histologic, and 臨床表現

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>IIPs</b></p></td></tr><tr><td><p><b>Type</b></p></td><td><p><b>Imaging/Histology</b></p></td><td><p><b>Clinical</b></p></td></tr><tr><td><p>IPF</p></td><td><p>UIP pattern: reticular opacities, honeycombing, traction bronchiectasis; peripheral, subpleural, &amp; basal</p></td><td><p>Sx &gt;12 mo</p><p>5-y mort ~80%</p></td></tr><tr><td><p>NSIP</p></td><td><p>Homogenous ground-glass opacities or consolid., reticular irreg lines; symmetric, peripheral, basal, subpleural. Cellular &amp; fibrotic subtypes, latter similar to UIP.</p></td><td><p>Sx mos–y</p><p>5-y mort 10%</p></td></tr><tr><td><p>COP</p></td><td><p>Patchy, migratory consolidations; subpleural &amp; peribronchial. Excessive proliferation of granulation tissue in small airways and alveolar ducts.</p></td><td><p>Post-infxn, XRT, rxn to drug. 5-y mort &lt;5%</p></td></tr><tr><td><p>AIP</p></td><td><p>Diffuse ground-glass opacities, consolidations with lobular sparing. Path similar to DAD.</p></td><td><p>Sx &lt;3 wk</p><p>6-mo mort 60%</p></td></tr><tr><td><p>DIP</p></td><td><p>Diffuse ground-glass opacities, reticular lines; lower zones. Peripheral Mφ in alveoli.</p></td><td rowspan="2"><p>30–50 yo <i>smokers</i></p><p>Sx wks–mos</p><p>Death rare</p></td></tr><tr><td><p>RB-ILD</p></td><td><p>Bronchial thickening, centrilobular nodules, patchy ground-glass opacities; upper lobe predom. Mφ in alveoli.</p></td></tr></tbody></table>

UIP, usual interstitial PNA (IP); IPF, idiopathic pulm fibrosis (_Lancet_ 2017;389:1941 & _NEJM_ 2018;378:1811); NSIP, non-specific IP; COP, cryptogenic organizing PNA; AIP, acute IP (Hamman-Rich syndrome); DIP, desquamative IP; RB-ILD, resp bronchiolitis-assoc ILD.

• Rx for IPF: suppl O2, pulm rehab, Rx for GERD, PHT screening, lung tx referral;

### pirfenidone (antifibrotic) or **nintedanib** (tyrosine kinase inhib mediating fibrogenic growth factors) ↓ rate of FVC decline (_NEJM_ 2014;370:2071 & 2083; _AJRCCM_ 2015;192:3)

high-dose steroids may be used for acute exacerbations, but no RCT data

• Steroids for other IIPs: NSIP (esp. cellular type) and COP (_AJRCCM_ 2000;162:571); ? benefit for AIP and DIP/RB-ILD (for which 病人 should stop smoking)

## Pulmonary infiltrates with eosinophilia (PIE) = eos on BAL ± peripheral blood

• **Allergic bronchopulmonary aspergillosis** (**ABPA**)

• Löffler’s syndrome: parasites/drugs → transient pulm infilt + cough, fever, dyspnea, eos

• Acute eosinophilic PNA (AEP): acute hypox febrile illness; Rx: steroids, tobacco cessation

• Chronic eosinophilic pneumonia (CEP): “photonegative” of CHF, typically in women

## Miscellaneous

• Pulm alveolar proteinosis (PAP): accumulation of surfactant-like phospholipids; white & gummy sputum; BAL milky fluid (_NEJM_ 2003;349:2527); Rx with lung lavage & GMCSF

• Langerhans cell granulomatosis (LCG): young ♂ smokers; apical cysts; PTX (25%)
